Article
Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients.
Anti-cancer drugs - 1 Sept 2015
Baas Jara M, Krens Lisanne L, Bos Monique M, Portielje Johanneke E A, Batman Erdogan, van Wezel Tom, Morreau Hans, Guchelaar Henk-Jan, Gelderblom Hans
Abstract excerpt
Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification of KRAS. We hypothesize that the activity of the RAS-induced pathway in patients with a KRAS mutation might be inhibited by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.